Canada Fentanyl Statistics 2026 | Deaths, Seizures, Spread & Facts

What is the Fentanyl Crisis in Canada?

Fentanyl is a synthetic opioid that is approximately 100 times more potent than morphine and 50 times more potent than heroin. In medical settings it has legitimate uses as an analgesic and anaesthetic — but it is the illegal, non-pharmaceutical fentanyl that has driven what the Public Health Agency of Canada (PHAC) describes as “one of the most serious public health crises Canada has ever faced.” Illegal fentanyl — manufactured in clandestine facilities, often using precursor chemicals from China, and distributed through criminal supply chains — entered the Canadian street drug supply in significant quantities beginning around 2013–2014, and by 2016 had transformed the overdose landscape so completely that British Columbia declared a provincial public health emergency in April of that year. Unlike heroin or cocaine, fentanyl is active in quantities measured in micrograms — a lethal dose of fentanyl is approximately two milligrams, a speck invisible to the naked eye — making contamination of other drugs (cocaine, MDMA, methamphetamine, counterfeit prescription pills) an immediate and unpredictable source of lethal risk for people who may not even know they are consuming an opioid. Carfentanil, a fentanyl analogue used in veterinary medicine to sedate large animals, is an estimated 100 times more potent than fentanyl itself and has been detected in Canadian drug samples.

Understanding Canada’s fentanyl statistics in 2026 requires holding two apparently contradictory facts simultaneously: the crisis peaked in 2023, deaths declined in 2024, and the early 2025 data shows a continued moderation — yet accidental poisoning remains the leading cause of death for Canadian males aged 20–49 and females aged 20–39, a fact confirmed by PHAC in its most recent surveillance update published in March 2026. The cumulative toll since national surveillance began in 2016 has now exceeded 55,032 apparent opioid toxicity deaths through September 2025 — a number comparable in scale to Canada losing an entire mid-sized city. The recent decline, documented carefully by PHAC and the Canadian Centre on Substance Use and Addiction (CCSA), is real but fragile: it is driven primarily by a reduction in fentanyl concentrations in the drug supply rather than structural improvements in treatment access or harm reduction infrastructure. Drug supply toxicity can shift rapidly, and new threats — including medetomidine (a veterinary sedative appearing in the drug supply since 2024), para-fluorofentanyl, and nitazenes (ultra-potent synthetic opioids of an entirely different chemical class) — represent emerging variables that could reverse the decline without warning. All statistics in this article are sourced from PHAC, Health Canada, the CBSA, and verified Canadian government and peer-reviewed publications.

Key Facts: Canada Fentanyl Statistics 2026

The following table captures the most essential and current Canada fentanyl facts 2026 — all drawn from PHAC’s opioid and stimulant-related harms surveillance dashboard (updated March 25, 2026), Health Canada, the Canada Border Services Agency, and verified federal government publications.

Data Sources: Public Health Agency of Canada (PHAC) — “Key Findings: Opioid- and Stimulant-related Harms in Canada” (health-infobase.canada.ca, data through September 2025, page updated March 25, 2026); PHAC — “Decline in Opioid-related Deaths in Canada” (December 11, 2025); CBC News — “Overdose Deaths in Canada Fell in 2024” (June 25, 2025); GlobalNews — “Opioid Deaths in Canada Fell 17% but 20 People Still Died Per Day in 2024” (June 25, 2025); Canada Border Services Agency — CBSA Launches Operation Blizzard (canada.ca, February 27, 2025); CBSA — Operation Blizzard results: 1.73 kg fentanyl seized (canada.ca, May 28, 2025); Government of Canada — “Strengthening Canada’s Border Security: Actions Taken to Date” (canada.ca, CIROC seizure data); CBC News — “Fentanyl Seizures Are Up at the U.S. Northern Border” (July 5, 2025); Library of Parliament — HillNotes “Canada–United States Border Security” (March 12, 2025)

These 26 facts tell a story of a crisis that is moderating but emphatically not over — and where the conditions for reversal remain present. The 55,032 cumulative deaths since 2016 represent a loss of life comparable in scale to the entire population of a city like Charlottetown, PEI, wiped out over nine years by a preventable public health emergency. The 17% decline from 2023 to 2024 (from 8,623 to 7,146 deaths) is genuinely meaningful — it saved an estimated 1,477 lives in a single year — but the 2024 total still represents nearly double the pre-pandemic 2019 toll of 3,742. The partial-year 2025 data (4,162 deaths through September 30) projects to a full-year figure below 2024 if the trend holds, but the CCSA’s analysis of BC data noted that deaths in April 2025 (165) were 4% higher than October 2024 (159), and EMS calls increased 41% between March and May 2025, signalling that the downward trend is neither uniform nor guaranteed. The shift in fentanyl’s share of deaths — from 74% in 2024 to 58% in January–September 2025 — reflects a genuine reduction in fentanyl concentration in the street drug supply, but also the emergence of fentanyl analogues (57%), medetomidine, and nitazenes filling the supply gap, making naloxone reversal more complex.

Canada Fentanyl Death Statistics 2016–2026

Apparent Opioid Toxicity Deaths in Canada — Annual Trend
(PHAC Opioid and Stimulant-related Harms Surveillance; updated March 25, 2026)

2016 |████████████████████████████                        2,861
2017 |████████████████████████████████████████            3,987
2018 |████████████████████████████████████████████        4,398
2019 |████████████████████████████████████              3,742 (pre-pandemic low)
2020 |████████████████████████████████████████████████████  6,214 (+66% surge — COVID)
2021 |████████████████████████████████████████████████████████ 7,560
2022 |████████████████████████████████████████████████████████ 7,328
2023 |█████████████████████████████████████████████████████████ 8,623 ← PEAK
2024 |████████████████████████████████████████████████████   7,146 (−17%)
2025*|████████████████████████████████████████████         ~5,600 (projected, Jan–Sep = 4,162)
      ─────────────────────────────────────────────────────────────────────────────────
      0     2,000    4,000    6,000    8,000    8,623
      *2025 = projection based on Jan–Sep PHAC data (4,162 deaths, 96% accidental)
      Fentanyl involved in 74% of 2024 deaths; 58% of Jan–Sep 2025 deaths

Data Sources: PHAC — Key Findings: Opioid- and Stimulant-related Harms in Canada (health-infobase.canada.ca, updated March 25, 2026); CBC News — “Overdose deaths in Canada fell in 2024” (June 25, 2025); CBC News — “Opioid deaths in Canada fell 17%” (August 21, 2025); PHAC — Decline in Opioid-related Deaths in Canada (December 11, 2025); HillNotes Library of Parliament — Canada–United States Border Security (March 12, 2025) citing PHAC data

The annual opioid death trajectory in Canada from 2016 to 2026 is a public health timeline defined by escalation, pandemic shock, and a partial correction whose permanence remains uncertain. The 2020 surge of +66% — taking deaths from 3,742 in 2019 to 6,214 in 2020 — is the most dramatic single-year increase in the entire series and is directly attributable to the compounding effects of the COVID-19 pandemic: disrupted drug supply chains led to increased supply variability and higher-toxicity batches; lockdowns isolated drug users from peers who could call for help; overdose prevention sites operated at reduced capacity; and the psychological distress of pandemic conditions drove increased drug use. 2021’s 7,560 deaths and 2023’s record 8,623 extended the pandemic-era crisis far beyond the immediate lockdown period, confirming that the overdose emergency had become structurally embedded rather than situationally driven. The 2024 decline to 7,146 (−17%) is the most encouraging single-year development in the crisis since national surveillance began — but even the head of the crisis response acknowledged publicly that 7,146 annual deaths, or roughly 20 Canadians per day, remains an extraordinary and unacceptable toll.

The shift in fentanyl’s share from a peak of approximately 86% of all opioid deaths in 2021 to 58% in the first nine months of 2025 does not straightforwardly mean the drug supply is safer — it means the supply is more chemically diverse. The Globe and Mail’s January 2026 analysis of Toronto’s Drug Checking Service found that average fentanyl concentration in tested samples fell from 5% in 2024 to 2% in 2025 — a genuine reduction. But the same data showed that the reduction in fentanyl was accompanied by the emergence of new adulterants including medetomidine (a veterinary sedative that causes extreme bradycardia and does not respond to naloxone), creating overdose scenarios that are qualitatively different from — and in some respects harder to reverse than — pure fentanyl overdoses. The Public Health Agency of Canada explicitly noted in its December 2025 analysis that “changes in the illegal drug supply are a likely factor in the recent decline in deaths,” and that the improvement correlates with “a decrease in fentanyl concentrations and high-risk drug combinations such as opioids mixed with benzodiazepines.” The supply-driven nature of the improvement is precisely what makes it fragile.

Fentanyl Deaths by Province and Demographics in Canada 2026

Opioid Toxicity Deaths by Province — Geographic Concentration
(PHAC data; 2024 full-year; Jan–Sep 2025 provincial share)

Provinces accounting for 80% of 2024 deaths (PHAC):
  British Columbia  |████████████████████████████████████████████  Largest share
  Alberta           |████████████████████████████████████          Second largest
  Ontario           |████████████████████████████████████          Second/Third (near tied)
  Together: BC + AB + ON = 80% of all 2024 opioid toxicity deaths

2025 (Jan–Sep): BC + AB + ON = 78% of all opioid toxicity deaths

Per-capita death rate ≥20 per 100,000 in 2024:
  Yukon      |████████████████████████████████████████████████████  Highest per capita
  Alberta    |████████████████████████████████████████████          ≥20 per 100,000
  Manitoba   |████████████████████████████████████████████          ≥20 per 100,000

Gender + Age:
  Male:    71% of 2024 deaths; 74% of Jan–Sep 2025 deaths
  Female:  29% of 2024 deaths; 26% of Jan–Sep 2025 deaths
  Age 30–39: 26% of Jan–Sep 2025 deaths (largest single age group)
  Age 40–49: 25% of Jan–Sep 2025 deaths
  Ages 30–49 combined: ~51% of all opioid toxicity deaths in 2025

Data Sources: PHAC — Key Findings: Opioid- and Stimulant-related Harms in Canada (health-infobase.canada.ca, March 25, 2026); CBC News — June 25, 2025 (provincial breakdown, per-capita data); GlobalNews — June 25, 2025; City of Toronto / Office of the Chief Coroner — “Annual Summary of Opioid Toxicity Deaths in Toronto — 2024” (October 17, 2025); PHAC — Decline in Opioid-related Deaths in Canada (December 11, 2025)

The geographic and demographic concentration of Canada’s fentanyl death toll is one of the most consistently documented findings in a decade of national surveillance — and it reveals a crisis that is simultaneously national in scope and profoundly unequal in distribution. British Columbia, Alberta, and Ontario together accounted for 80% of all opioid toxicity deaths in 2024 (78% in the first nine months of 2025), despite containing approximately 65% of Canada’s total population — confirming that these three provinces are experiencing the crisis at above-average intensity relative to their population size. The per-capita leader in 2024 was Yukon, where fentanyl’s penetration into remote communities with limited harm reduction services has produced death rates exceeding 20 per 100,000 people — a per-capita burden comparable to the hardest-hit US states. Alberta and Manitoba also recorded per-capita rates above the 20 per 100,000 threshold in 2024, a fact that sits in tension with Alberta’s strong economic growth narrative and confirms that prosperity and overdose vulnerability are not inversely correlated in any simple way.

The age and gender demographics of the death toll confirm what nine years of PHAC surveillance have established as structural patterns. 71–74% of opioid toxicity deaths occur among males, a pattern observed consistently across all years and attributed to a combination of higher rates of substance use disorder among men, lower rates of treatment-seeking, and greater exposure to high-risk drug environments. The 30–39 age cohort represents the single largest share of both 2024 and 2025 deaths — precisely the working-age population that would otherwise be in their most economically productive decade. That accidental poisoning is the leading cause of death for Canadian males aged 20–49 and females aged 20–39 — a status confirmed by PHAC in its March 2026 dashboard update — frames the fentanyl crisis not as a marginal social problem but as the primary cause of death for working-age Canadians, surpassing motor vehicle accidents, heart disease, and cancer in that age bracket. The 96% accidental rate in the 2025 data confirms that the overwhelming majority of these deaths are not suicides or intentional overdoses — they are people who ingested what they believed was a known substance and encountered a lethal concentration of fentanyl or its analogues without warning.

Canada Fentanyl Seizures and Border Enforcement Statistics 2026

CBSA Fentanyl Seizures and Border Enforcement — 2024–2025
(CBSA official seizure statistics; canada.ca; CBSA 2025 Year in Review)

CBSA Fentanyl Seized — 2024:
  Total: 4.9 kg across 28,325 total drug seizures
  Notable: Single seizure of 4.1 kg = majority of annual total (775% quantity increase vs 2023)

Operation Blizzard Results (Feb–May 2025):
  116 fentanyl seizures → 1.73 kg (1.44 kg destined for US; 0.26 kg other countries)
  Provinces: British Columbia, Quebec, Alberta
  2,600+ total suspected narcotics and precursor shipments seized
  67.5% of seizures = drugs coming TO Canada from the US
  17.5% of seizures = narcotics going TO the United States

CIROC (Dec 2024–Jan 2025):
  ~100 lbs (~45 kg) fentanyl + ~16,000 synthetic opioid pills seized
  Federal, provincial, municipal law enforcement collaboration

US Northern Border (CBP, Oct 2024–May 2025):
  26 kg fentanyl seized — vs 19.5 kg in all of 2023–24
  Southern US border comparison: 3,700 kg in same period
  Canada = 0.2% of large-seizure fentanyl entering US
  99% of large US border fentanyl seizures (2013–2024) came from Mexico

Data Sources: Canada Border Services Agency — “CBSA Launches Operation Blizzard” (canada.ca, February 27, 2025); CBSA — “CBSA Seizes 1.73 kg of Fentanyl…During Operation Blizzard” (canada.ca, May 28, 2025); Government of Canada — “Strengthening Canada’s Border Security: Actions Taken to Date” (canada.ca, September 22, 2025); Library of Parliament — HillNotes “Canada-United States Border Security: Drug Trafficking and Irregular Migration” (March 12, 2025); CBC News — “Fentanyl Seizures Are Up at the U.S. Northern Border” (July 5, 2025); Manhattan Institute — “Fentanyl at the Gates” (July 14, 2025)

The fentanyl seizure statistics at Canada’s borders in 2025–2026 must be read against the political context in which they have been collected and reported. The CBSA’s 4.9 kilograms of fentanyl seized in all of 2024 — while representing a 775% volume increase from 2023 — is a number whose headline figure is almost entirely attributable to a single large interception of 4.1 kilograms. Outside that single bust, routine CBSA fentanyl seizures remain modest by volume, reflecting both the challenge of detecting microgram-active substances in high-volume cargo streams and the reality that the primary domestic fentanyl supply chain in Canada is not predominantly an import-at-the-border problem but a distribution-and-manufacturing one. The CBSA’s Operation Blizzard, launched in February 2025 in response to US pressure on the Canada-fentanyl narrative, focused specifically on mail, air freight, and sea containers — the channels most likely to carry precursor chemicals and finished product — and yielded 116 fentanyl seizures totalling 1.73 kg, with a notable finding: 67.5% of all narcotics seized during the operation were drugs coming TO Canada from the United States, rather than the reverse, complicating the framing of Canada as a significant source of US fentanyl supply.

The US-Canada fentanyl border data is perhaps the most politically charged statistical dataset in this entire article, given that the Trump administration cited fentanyl trafficking as a justification for tariffs against Canada in 2025–2026. The US Customs and Border Protection data shows that 26 kilograms of fentanyl were seized at the northern border from October 2024 to May 2025 — a number that is simultaneously a genuine increase from the prior year and an almost insignificant fraction of the ~3,700 kilograms seized at the US-Mexico southwestern border in the same period. The Manhattan Institute’s peer-reviewed July 2025 analysis of all large fentanyl seizures at US land borders from 2013 to 2024 found that 99% of pill-form and 97% of powder-form fentanyl in large seizures (>1 kg powder or >1,000 pills) came from the Mexico border, with Canada-border large seizures described as “relatively rare.” Canada’s Fentanyl Czar Kevin Brosseau stated publicly: “The greater source of this problem for the US is Mexico and this is one more study that confirms that.” The data supports his assessment.

Canada’s Fentanyl Supply — Drug Checking Data and Emerging Threats 2026

Fentanyl Concentration Trends in Canadian Street Drug Supply
(Health Canada Drug Analysis Service; Toronto Drug Checking Service; BC Drug Checking; Globe and Mail January 2026)

TORONTO Drug Checking Service — Fentanyl Concentration:
  2024 average: 5% fentanyl in tested samples (1,200 samples)
  2025 average: 2% fentanyl in tested samples (1,300 samples)
  Change: −60% reduction in average fentanyl concentration

BRITISH COLUMBIA — Fentanyl Concentration (provincial median):
  2023 peak: 11.0% in mid-2023
  Early 2025: 5.1%
  Through June 2025: 7.1% (provincial median, 47,919 opioid samples)

EMERGING THREATS ENTERING SUPPLY (2025–2026):
  ★ Medetomidine — veterinary sedative; extreme bradycardia; NOT reversed by naloxone
  ★ Para-fluorofentanyl — fentanyl analogue; increasing share of deaths (57% analogues in 2025)
  ★ Nitazenes — ultra-potent synthetic opioid; different chemical class; naloxone-resistant
  ★ Carfentanil — veterinary tranquilizer; ~100× more potent than fentanyl; occasional detection

Data Sources: Globe and Mail — “Opioid Deaths Have Declined Sharply in Canada: These Five Factors Help Explain Why” (January 30, 2026); ScienceDirect / BCCSU — “Temporal and Regional Associations Between Fentanyl Concentrations in the Unregulated Drug Supply and Drug-related Mortality in British Columbia” (February 14, 2026); CCSA/CCENDU — “Recent Trends in Opioid-Related Toxicity Deaths in Canada, Issue 6” (August 2025); PHAC — Key Findings dashboard (March 25, 2026); PHAC — Decline in Opioid-related Deaths in Canada (December 11, 2025)

The drug supply data from 2025 provides the most granular explanation available for why Canadian opioid deaths have declined — and why that decline remains precarious. The Toronto Drug Checking Service’s finding that average fentanyl concentration in tested samples fell from 5% in 2024 to 2% in 2025 (across approximately 1,300 samples) represents a genuinely significant reduction in the potency of the street fentanyl supply in Canada’s largest city. The BCCSU analysis of 47,919 opioid samples tested in British Columbia between October 2018 and June 2025 similarly found that provincial median fentanyl concentration peaked at 11.0% in mid-2023 — the year of Canada’s record 8,623 deaths — and fell to 5.1% in early 2025, with a partial rebound to 7.1% by June 2025 suggesting the decline may be levelling off. The mathematical relationship between supply concentration and deaths was quantified in the BCCSU study: each 1-percentage-point increase in median fentanyl concentration was associated with a 0.072 increase in the monthly drug-related mortality rate per 100,000 population — confirming that supply toxicity is a direct and measurable driver of mortality outcomes.

The emergence of medetomidine as a drug supply adulterant is the most clinically alarming 2025–2026 development in the Canadian fentanyl crisis. Medetomidine is an alpha-2 adrenergic agonist used in veterinary medicine as a sedative and anaesthetic — it is chemically unrelated to fentanyl and operates through a completely different biological mechanism. Its appearance in street drug samples, noted across multiple provinces in 2025, creates overdose presentations involving extreme bradycardia (dangerous slowing of the heart) that does not respond to naloxone, the standard opioid reversal agent. This means that first responders administering naloxone to a medetomidine-involved overdose may observe no response and assume the dose was inadequate, when in fact the problem is a different drug class entirely. PHAC’s December 2025 analysis flagged medetomidine alongside the decline in benzodiazepine mixing (previously a major death contributor) as a key dynamic reshaping the drug supply toxicity profile. The 57% of January–September 2025 opioid deaths that involved fentanyl analogues — a category that includes para-fluorofentanyl, acetylfentanyl, carfentanil, and others — confirms that the supply-side evolution is toward increased chemical diversity, not simplification, making harm reduction and clinical response more complex year by year.

Canada’s Policy Response to the Fentanyl Crisis in 2026

Key Federal Policy Responses — Canada's Fentanyl Crisis (2024–2026)
(canada.ca; Government of Canada official announcements)

FINANCIAL INVESTMENT:
  $1.3 billion — Canada Border Plan (December 2024)
  Expanded enforcement: 1,000 new CBSA officers; drones; Black Hawk helicopters; surveillance towers

ENFORCEMENT OPERATIONS:
  Operation Blizzard (Feb–May 2025): 2,600+ seizures; 1.73 kg fentanyl
  CIROC operation (Dec 2024–Jan 2025): ~45 kg fentanyl; 16,000+ pills
  New power: Police can search Canada Post mail for fentanyl (general warrant)

LEADERSHIP:
  Kevin Brosseau — Canada's Fentanyl Czar (appointed February 11, 2025)
  Daily communication with US counterparts

HARM REDUCTION IN OPERATION (ongoing):
  Supervised consumption sites: BC, Alberta, Ontario, others
  Naloxone distribution: National take-home program
  Opioid agonist therapy (OAT): Methadone, buprenorphine access expanded
  Drug checking services: Toronto, BC — publicly operated
  Safe supply programs: Hydromorphone; contested provincially

LEGISLATIVE CHANGES (criminal code / CDSA):
  Law enforcement exemptions in drug production/trafficking investigations
  Faster scheduling of drug precursor chemicals
  Lawful access to basic information in early-stage investigations
  Electronic service provider data retention for investigations

Data Sources: Government of Canada — “Strengthening Canada’s Border Security: Actions Taken to Date” (canada.ca, September 22, 2025); CBSA — “CBSA Launches Operation Blizzard” (canada.ca, February 27, 2025); PHAC — “Decline in Opioid-related Deaths in Canada” (December 11, 2025); CBC News — “Overdose deaths are falling. Will fentanyl crackdowns change that?” (August 2025); CCSA — “Recent Trends in Opioid-Related Toxicity Deaths in Canada” (August 2025)

Canada’s policy response to the fentanyl crisis in 2026 operates simultaneously on two largely separate tracks — enforcement and harm reduction — with political tension between them that has intensified rather than diminished as death counts have (partially) declined. The $1.3 billion Border Plan announced in December 2024, expanded in February 2025, is primarily an enforcement investment: new CBSA officers, drone and counter-drone technology, Black Hawk helicopters for aerial surveillance, and mobile surveillance towers positioned at high-traffic border corridors. The appointment of Kevin Brosseau as Canada’s Fentanyl Czar in February 2025 — with an explicit mandate to coordinate daily with US counterparts — was a direct response to Trump administration pressure linking fentanyl trafficking to tariff policy. The subsequent Operation Blizzard, which ran from February to May 2025 and produced 2,600+ seizures including 1.73 kg of fentanyl, generated significant domestic media coverage and served both a genuine interdiction function and a political signalling one: Canada demonstrating to Washington that it was taking the fentanyl file seriously.

The harm reduction infrastructure — supervised consumption sites, naloxone distribution, opioid agonist therapy, and drug checking services — represents a fundamentally different logic: reducing the danger of drug use for people currently using, rather than stopping drug supply. The Globe and Mail’s January 2026 analysis of factors behind the 2024 death decline identified harm reduction program operation and expansion of OAT access as important contributors — alongside the supply-side reduction in fentanyl concentration. The political contestation around supervised consumption sites has intensified in Alberta and Ontario particularly, where provincial governments have moved to restrict or close sites. Public health researchers and the Canadian Centre on Substance Use and Addiction have consistently documented that harm reduction interventions reduce deaths, and that their removal is associated with increased mortality. The BC public health emergency, now entering its 10th year since its declaration in April 2016, stands as the most enduring institutional acknowledgment that the fentanyl crisis demands a sustained, emergency-level public health response — one that has reduced per-death rates in BC through harm reduction investment even as the overall national toll has remained enormous.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE